Harbour Investments’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$397K Buy
888
+395
+80% +$184K 0.01% 1164
2025
Q4
$224K Buy
493
+29
+6% +$12.5K ﹤0.01% 1225
2025
Q3
$182K Buy
464
+61
+15% +$25.5K ﹤0.01% 1282
2025
Q2
$179K Sell
403
-7
-2% -$3.23K ﹤0.01% 1224
2025
Q1
$199K Buy
410
+68
+20% +$31.7K 0.01% 1100
2024
Q4
$138K Buy
342
+1
+0.3% +$464 ﹤0.01% 1205
2024
Q3
$159K Sell
341
-44
-11% -$21.1K ﹤0.01% 1115
2024
Q2
$180K Buy
385
+15
+4% +$6.51K 0.01% 988
2024
Q1
$155K Buy
370
+57
+18% +$24.1K 0.01% 1023
2023
Q4
$127K Buy
313
+51
+19% +$18.8K 0.01% 1040
2023
Q3
$91.1K Sell
262
-13
-5% -$4.55K ﹤0.01% 1087
2023
Q2
$96.8K Buy
275
+6
+2% +$2.02K ﹤0.01% 1074
2023
Q1
$84.8K Sell
269
-65
-19% -$19.5K ﹤0.01% 1116
2022
Q4
$96.5K Buy
334
+45
+16% +$13.7K 0.01% 1019
2022
Q3
$81K Hold
289
0.01% 1066
2022
Q2
$81K Buy
+289
New +$77.4K 0.01% 1066
2021
Q4
$98K Sell
444
-838
-65% -$163K 0.01% 976
2021
Q3
$233K Buy
1,282
+148
+13% +$28.9K 0.01% 947
2021
Q2
$229K Buy
1,134
+102
+10% +$21.3K 0.01% 981
2021
Q1
$222K Buy
+1,032
New +$227K 0.01% 918

Other funds holding VRTX

Harbour Investments's VRTX Position: Q1 2026 in Review

Harbour Investments increased its Vertex Pharmaceuticals (VRTX) stake by 80% in Q1 2026, buying an estimated $184K and bringing the position to 888 shares worth $397K. The position accounts for 0.01% of the portfolio, ranked #1164.

Harbour Investments first reported a position in VRTX in Q1 2021 and has held it in 20 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

  • Harbour Investments held 888 shares of Vertex Pharmaceuticals worth $397K as of Q1 2026.
  • Harbour Investments bought 395 Vertex Pharmaceuticals shares in Q1 2026, an estimated $184K.
  • Vertex Pharmaceuticals made up 0.01% of Harbour Investments's portfolio in Q1 2026, its #1164 holding.
  • Harbour Investments first reported a position in Vertex Pharmaceuticals in Q1 2021 and has held it in 20 quarters since.
  • 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on Harbour Investments's 13F filing for Q1 2026, filed 15 May 2026.